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Abstract
Mannose binding lectin (MBL2) is a soluble pattern recognition receptor that is key to generating innate immune responses to invasive
infection, including against the cardinal Gram-negative bacterium Neisseria meningitidis. Individuals homozygous or heterozygous for any of
three variant alleles of MBL2 (O/O or A/O genotypes) have deficient concentrations of MBL2 in circulating blood, but previous studies
linking MBL deficiency to susceptibility to meningococcal disease have not revealed a consistent association. We genotyped 741 patients
with microbiologically – proven meningococcal disease and correlated MBL2 genotype with plasma bacterial load of N. meningitidis with
blood samples taken during hospital admission. We show that individuals with genotypes compatible with MBL2 deficiency have higher
measurable levels of bacterial plasma genomic load with the greatest effect seen in children <2 years of age. However, the overall impact of
this is minor, because there was no evidence that such genotypes are more common in children with meningococcal disease compared with
uninfected cohorts. The findings suggest that MBL2 supports innate immune defence against meningococcal disease in the early months of
life, before acquired immunity is sufficiently robust for effective natural protection.
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Background
Infections caused by Neisseria meningitidis (N. meningitidis)
remain an important cause of morbidity and mortality, despite
the implementation of glycoconjugate vaccination in some
parts of the world. Protection against meningococcaemia relies
on the bactericidal activity of blood through activation of the
complement cascade. In adults, this primarily occurs via
specific immunoglobulin (the classical pathway), although in
early life, innate mechanisms are critically important. The most
common innate defect currently known is mannose-binding
lectin (MBL2) deficiency, which affects c. 5–30% of adults [1].
Although studies of the relationship between MBL2 deficiency
and susceptibility to meningococcal infection have yielded
conflicting information [2–5], there is evidence that low levels
of this soluble pattern recognition molecule are associated
with worse outcomes during sepsis and septic shock [6]. For
example, a multi-centre study of 88 children by Faber and
colleagues, suggested that MBL exon 1 structural variants
are more common in meningococcal disease patients com-
pared to the general population, particularly in those aged
<24 months [4].
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In humans, MBL2 is encoded by 4 exons on the long arm
of chromosome 10; polymorphism of exon 1 or of several
highly pleomorphic promoter regions results in seven
common haplotypes of MBL2 and variable plasma concen-
trations of MBL2 protein. Individuals not possessing the
wild-type gene ‘A’ but who are instead homozygous or
heterozygous for any of the three variant alleles (‘B’,
rs1800450; ‘C’, rs1800451rs; ‘D’, rs5030737; or collectively
‘O’) are unable to form high order oligomers. The O/O or
A/O genotypes result in plasma MBL2 concentrations c. 1%
and 10% of A/A individuals, respectively [7]. A recent
meta-analysis estimated O allele frequency as 0.23 in the
white European general population [5]. Additional effects of
promoter region variation is less well understood, although
Y variants of the 221 G/C (rs7096206) base pair X/Y
polymorphism tend to have higher levels of circulating MBL2
protein [8].
In the UK, rollout of the serogroup C glycoconjugate
vaccination programme commenced November 1999. In the
current study, we used a large, well-characterised, pre-conju-
gate vaccine cohort to determine whether MBL2 deficiency is
associated with meningococcal infection acquisition in young
children, and also whether there may be an association with
measured plasma bacterial load or meningococcal disease
severity/outcome.
Methods
Patients, samples and quantitative meningococcal PCR
The national Meningococcal Reference Unit for England and
Wales (MRU) offers confirmatory testing on samples
submitted from cases of suspected meningococcal infection.
Testing includes both routine microbiological culture in
addition to non-culture based diagnosis using EDTA-treated
blood samples, as described previously [9]. Patient and
sample data were included in this analysis if an EDTA--
treated blood sample had been submitted to the MRU and
the patient was subsequently proven to have meningococcal
disease on the basis of culture or PCR of material from an
invasive site, and informed consent had been obtained. The
Multiplex polymerase chain reaction (PCR)-based assay for
detecting specific DNA sequences, including the N. menin-
gitidis-specific capsule transport gene (ctrA), provides accu-
rate data regarding genomic bacterial load in the range log10
3–9 copies/mL whole blood [10]. Ethics committee approval
for the study was granted by the Public Health Laboratory
Service (now Public Health England) and the Ethics Com-
mittee of the Sheffield Teaching Hospitals NHS Foundation
Trust (Sheffield, England).
MBL2 genotyping
Where residual DNA was available after processing of EDTA
blood received in the period January 1999 through to Decem-
ber 1999 for quantitative meningococcal PCR, MBL2 structural
genotypes were determined by heteroduplex and linkage
disequilibrium analyses, as previously described [8,11]. This
cohort was unlikely to be exposed to glycoconjugate vaccine.
To determine allele frequency in a contemporary healthy
population, a subset of the 14 000 children participating in the
Avon Longitudinal Study of Parents and Children (ALSPAC)
who had been genotyped for known structural and promoter
polymorphisms of the MBL2 gene were used as a normal,
unselected control group (see http://www.bristol.ac.uk/alspac/).
Statistical analysis
Based on previous suggestions that risk of N. meningitidis
infection maybe increased in individuals possessing the defec-
tive MBL2 allele and our findings of poor outcomes from
infection being related to N. meningitidis bacterial load and
infecting serogroup, we hypothesized:
1. that we may be able to identify an increased proportion of
susceptible individuals in our national cohort compared to a
contemporary control data set (the Avon cohort) and,
2. that an age-related effect of MBL genotype on bacterial load
may have an impact on the frequency of adverse outcomes.
Given the differences found in circulating levels of MBL
associated with various allele combinations, we assumed that
the most likely biologically plausible difference in outcome
would be between O/O homozygous and the ‘wild-type’ (A/)
populations. Following preliminary testing by univariate analy-
ses (using chi squared or Student’s T test, as appropriate),
individuals with alleles resulting in structurally variant MBL2
(i.e. B, C and D) were grouped together as ‘O’ therefore, in
order to identify whether MBL2 deficiency contributed to
mortality or measured plasma bacterial load using multivariate
regression modelling. Bacterial load data were log10 trans-
formed to assume a normal distribution. Statistical analysis was
performed using SPSS software (version 20; IBM) and Prism
(version 6; GraphPad, Inc.). Interactions were considered
significant at p <0.05.
Results
Patients
MBL2 genotyping was conducted on 741 samples, and collated
with clinical and microbiological data. The baseline demo-
graphic and bacteriologic characteristics of this meningococcal
cohort were similar to those described previously relating to
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1910 EDTA-treated blood samples from patients with proven
meningococcal disease, collected January 1999 – December
2001 [9] which included the current samples analysed here.
The median age [IQR] was 5 [1-17] years, 50.9% were male
gender and the meningococcal infection mortality rate was
8.6%. Infections were due mostly to serogroup B (45.9%) and
C (36.3%) N. meningitidis, as was typical of this pre-vaccine era.
The demographic, clinical and microbiological data derived
from the total cohort of meningococcal disease patients, and
the subset genotyped at MBL2 are each summarised in Table 1.
Allele frequency & susceptibility to meningococcal infection
The frequency of O/O genotype was 0.072 (53/741) in patients
with confirmed meningococcal infection, in comparison to
0.056 (59/1046) in individuals from the healthy control popu-
lation (p NS). Excluding infected patients of non-Caucasian
self-reported ethnicity resulted in an allele frequency of 0.065.
The frequency of A/O carriage in patients was 0.332
compared to 0.322 in the healthy control population. As
expected, carriage of the B variant minor allele was most
common (0.15) whereas the C and D alleles were less
commonly found (0.02 and 0.07 respectively).
Observed allele frequencies did not differ by age group and
no increased risk of meningococcal infection was seen in O/O
genotype children <1 year of age (9/98 meningococcal patients
vs. 8/104 healthy controls, p NS). The age-specific frequencies
of SNPs found the current population in comparison to the
cohort recently described by Bradley and colleagues [5] are
detailed in Table 2.
Survival after meningococcal infection
No significant difference was seen in the survival rate of
patients homozygous for O alleles (O/O) compared to patients
with A/O or A/A combinations (92.3% vs. 91.3% respectively; p
NS, chi squared test). Survival rates remained similar when
stratified by patient age group (data not shown).
Bacterial load during infection
Neisseria meningitidis quantification data were available for 307/
741 patients for whom an EDTA-treated blood sample was
received by the reference laboratory. The bacterial load
measured tended to be higher in patients homozygous for O
alleles (O/O, n = 21) than in ‘wild-type’ patients (A/,
n = 285) (median copy number [IQR], 4.72 [3.66–5.86] vs.
4.30 [3.53–5.38]; p 0.054, T-test).
Patients <2 years of age with the O/O genotype (n = 4) had
significantly higher bacterial loads than those patients with an
A/ genotype (median [IQR], 6.67 [4.99–7.61] vs. 4.14 [3.47–
5.33]; p 0.007, T-test), regardless of additional MBL2 promoter
SNP polymorphisms (X/Y variants, see Fig. 1a). In general the
bacterial load measured in O/O genotype patients appeared to
diminish with age, whereas no similar decline was seen in the
‘wild-type’ population, but was non-significant (Pearson’s
correlation, p NS, see Fig. 1b).
Factors affecting bacterial load
To assess the combination of factors affecting the measured
circulating bacterial load, we included O/O genotype homo-
zygosity into our previously described multivariate model for
bacterial load [9]. Both serogroup C infection and possession
of the MBL2 O/O genotype but not patient age, significantly
contributed towards an increased plasma bacterial load; O/O
genotype was associated with a 1.858 log10 higher (95% CI,
1.019–3.388, p 0.043) and serogroup C infection with a 1.414
log10 higher N. meningitidis plasma bacterial load (95% CI,
1.036–1.928, p 0.029), in a sample of 300 patients for whom
data was available with all other factors being equal (Table 3).
Discussion
We show, for the first time, that individuals with genotypes
compatible with MBL2 deficiency have higher measurable
levels of bacterial plasma genomic load during a defined
invasive infection. We found no evidence that such genotypes
are more common overall in children with meningococcal
TABLE 1. Baseline demographic features for the MBL data-
set in comparison to the complete bacterial load dataset
ALL
Genotyped
at MBL2
Number of patients 1910 741
Male gender, % 50.5a 50.9b
Mortality, n (%) 170 (8.9)c 63 (8.6)
Age, median years [IQR] 5 [1–18] 5 [1–17]
Infecting Neisseria meningitidis
serogroup, n (%)
A 1 (0.1) 1 (0.1)
B 1020 (54.1) 334 (45.9)
C 623 (33) 264 (36.3)
Y 8 (0.4) 0 (0)
W135 31 (1.6) 4 (0.6)
Ungrouped 203 (10.8) 124 (17.1)
Method of diagnosis
PCR only 984 (51.5) 336 (45.3)
Culture only 251 (13.1) 127 (17.1)
Both PCR & culture 661 (34.6) 271 (36.6)
Pre-hospital antibiotics
received, n (%)
275 (31.4) 138 (34)
Time to PCR sample submission,
median days (range)
0 (0–25) 0 (0–11)
Proportion PCR samples submitted
within 24 h of hospital admission
57.5 60.4%
Ethnicity, n (%)
White 937 (96.9) 414 (96.7)
Pakistani 12 (1.2) 4 (0.19)
Mixed 12 (1.2) 8 (1.9)
Other 6 (0.6) 2 (0.4)
IQR, interquartile range; PCR, polymerase chain reaction.
aInformation not available: 16/1910.
bInformation not available: 4/741.
cInformation not available: 21/1910.
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TABLE 2. Age-specific frequencies of MBL2 single nucleotide polymorphisms
Age-group WTCC controls
(from Bradley and
colleagues [5])
(n = 5196)ALL (n = 741) Aged < 1 (n = 109) Aged 1–2 (n = 87) Aged < 2 (n = 196) Aged ≥ 2 (n = 545)
Genotype n, (frequency)
AA 442 (0.6) 63 (0.58) 52 (0.6) 115 (0.59) 327 (0.6) 3080 (0.59)
AO 246 (0.33) 38 (0.35) 30 (0.34) 68 (0.35) 178 (0.33) 1826 (0.35)
AB 153 (0.21) 22 (0.2) 19 (0.22) 41 (0.21) 112 (0.21) 1128 (0.22)
AC 24 (0.03) 5 (0.05) 5 (0.06) 10 (0.05) 14 (0.03) 154 (0.03)
AD 69 (0.07) 11 (0.10) 6 (0.07) 17 (0.09) 52 (0.10) 544 (0.10)
OO 53 (0.07) 8 (0.07) 5 (0.06) 13 (0.07) 40 (0.07) 290 (0.06)
BB 23 (0.03) 3 (0.03) 1 (0.01) 4 (0.02) 19 (0.04) 111 (0.02)
BC 4 (0.005) 1 (0.01) 2 (0.02) 3 (0.03) 1 (0.002) 29 (0.01)
BD 14 (0.02) 2 (0.02) 0 2 (0.01) 12 (0.02) 107 (0.02)
CC 3 (0.004) 1 (0.01) 0 1 (0.005) 2 (0.004) 2 (0.00)
CD 3 (0.004) 0 1 (0.01) 1 (0.005) 2 (0.004) 13 (0.00)
DD 6 (0.008) 1 (0.01) 1 (0.01) 2 (0.01) 4 (0.07) 29 (0.01)
Simplified genotype
A 1130 (0.76) 164 (0.75) 134 (0.77) 136 (0.60) 832 (0.76) 7986 (0.77)
O 352 (0.24) 54 (0.25) 40 (0.23) 94 (0.41) 258 (0.24) 2406 (0.23)
B 217 (0.15) 31 (0.14) 23 (0.13) 54 (0.23) 163 (0.15) 1485 (0.14)
C 37 (0.02) 8 (0.04) 8 (0.05) 16 (0.07) 21 (0.02) 199 (0.02)
D 98 (0.07) 15 (0.07) 9 (0.05) 24 (0.10) 74 (0.07) 722 (0.07)
(a) (b)
FIG. 1. Plasma bacterial load measurements (log10 copies/mL) of patients with confirmed Neisseria meningitidis infection in relation to, (a) MBL2
structural and promoter genotype combinations in patients aged below 2 years, and (b) year of age (to 10 years), according to MBL structural
genotype (either A/ or O/O).
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infection, even in children <1 year of age, consistent with the
large case–control study by Bradley and colleagues [5].
Although our sample did not reveal an effect of MBL2
genotype on susceptibility to meningococcal invasion and
disease, our data suggests that control of early bacterial
replication within blood may be impeded, as is expected with
this defect of innate immunity. This implies a subtle contribu-
tion by MBL2 to innate immunity, that is insufficient to render
individuals grossly susceptible to invasive disease. Previous in
vitro data suggests that MBL phenotype together with circu-
lating levels of IL1b and IL10 may have a combinatorial effect
on the pro-inflammatory cytokine cascade [12], and that MBL2
promotes non-opsonic phagocytosis of N. meningitidis by
human macrophages [13]. Thus, in individuals homozygous
for the defective MBL2 alleles, a reduced level of MBL2 and
associated reduction in the levels of inflammation may give rise
to a higher detected peripheral bacterial load. An additional
contributing factor is likely to be the nature of the infecting
serogroup; as replicated here, we have previously demon-
strated that patients infected with serogroup C N. meningitidis
have significantly higher plasma bacterial loads [9]. Higher
bacterial loads worsen disease severity, but we were not able
to demonstrate conclusively a direct relationship between
MBL2 genotype, bacterial genomic load, and mortality in this
study, because of the small number of deaths in the sample.
The effect of MBL2 deficiency on measured plasma bacterial
loads was most marked in the first 2 years of life underscoring
the important high-risk period of early infancy prior to the
development of specific bactericidal anti-meningococcal anti-
bodies. Interestingly, MBL2 variants associated with MBL
deficiency also are more frequent in HIV-infected children
with more rapid HIV-1 disease progression and CNS impair-
ment, with the greatest effect observed in children younger
than 2 years [14].
The strengths of this study include the relatively large
sample and both the validation of meningococcal disease and
measurement of bacterial genomic load by a national reference
laboratory. Weaknesses include the relative inaccuracy of
history-obtained ethnicity data; in the era of whole genome
sequencing the ability to define ancestry by genetic clustering is
the gold standard. This study was also a retrospective analysis
of previously collated data, although the allele frequency and
disease incidence rates are in keeping with other large
multi-centre studies.
Conclusions
In conclusion, in children with genotypes associated with
deficiency of MBL2 there is an age-related inverse correla-
tion with the number of bacteria present in the circulation,
highlighting the importance of developing protective humoral
response mechanisms and underscoring the requirement of
an effective vaccine to protect this at-risk age group. These
data support the assertion that MBL2 deficiency per se does
not grossly increase the risk of acquiring meningococcal
infection, but appears to be involved in controlling bacterial
numbers in younger children once acquisition has occurred.
In view of the association between plasma bacterial load and
death [9], it is likely that larger studies would show a
relationship between MBL2 genotype and mortality in
Gram-negative infection.
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